Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Conditions
Glioblastoma Multiforme
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Southern California, Los Angeles, California, United States
Sutter Health Research Institute, San Francisco, California, United States
Saint John Cancer Institute, Santa Monica, California, United States
Georgia Cancer Center (Augusta University), Augusta, Georgia, United States
Ochsner Health, New Orleans, Louisiana, United States
Atlantic Health (Overlook Medical Center), Summit, New Jersey, United States
Northwell Health, New York, New York, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Baylor Scott & White Health, Dallas, Texas, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Study leads
Thomas Chen, MD, PhD
Study Chair
NeOnc Technologies Holdings, Inc.
Josh Neman, PhD
Study Director
NeOnc Technologies Holdings, Inc.
No study contact email or phone is listed for this trial.